Cargando…
The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy
PURPOSE: The purpose of this study is to investigate the role of fibroblast growth factor receptor 4 (FGFR4) polymorphism in esophageal cancer after chemoradiotherapy (CRT). MATERIALS AND METHODS: Peripheral blood samples from 244 patients treated with CRT for esophageal squamous cell carcinoma were...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720088/ https://www.ncbi.nlm.nih.gov/pubmed/25989802 http://dx.doi.org/10.4143/crt.2015.018 |
_version_ | 1782411040815841280 |
---|---|
author | Shim, Hyun-Jeong Shin, Min-Ho Kim, Hee-Nam Kim, Jo-Heon Hwang, Jun-Eul Bae, Woo-Kyun Chung, Ik-Joo Cho, Sang-Hee |
author_facet | Shim, Hyun-Jeong Shin, Min-Ho Kim, Hee-Nam Kim, Jo-Heon Hwang, Jun-Eul Bae, Woo-Kyun Chung, Ik-Joo Cho, Sang-Hee |
author_sort | Shim, Hyun-Jeong |
collection | PubMed |
description | PURPOSE: The purpose of this study is to investigate the role of fibroblast growth factor receptor 4 (FGFR4) polymorphism in esophageal cancer after chemoradiotherapy (CRT). MATERIALS AND METHODS: Peripheral blood samples from 244 patients treated with CRT for esophageal squamous cell carcinoma were assessed for the role of FGFR4 genotype on treatment response and survival. RESULTS: A total of 94 patients were homozygous for the Gly388 allele, and 110 were heterozygous and 40 homozygous for the Arg388 allele. No significant association was found between the FGFR4 genotype and clinicopathological parameters. However, patients carrying the Gly388 allele showed a better overall response rate than Arg388 carriers (p=0.038). In addition, Gly388 allele patients at an earlier stage showed better overall survival (OS) and progression-free survival than Arg388 carriers. Among these, the Gly388 allele showed significantly improved OS compared to Arg388 carriers in the lymph node (LN) metastasis group (p=0.042) compared to the no LN metastasis group (p=0.125). However, similar survival outcomes were observed for advanced-stage disease regardless of genotype. CONCLUSION: This result suggests that the role of FGFR4 Gly388 in treatment outcomes differs according to esophageal cancer stage. It showed a predictive role in the response of esophageal cancer patients to CRT with a better trend for OS in Gly388 than Arg388 carriers in the early stages. In particular, LN-positive early-stage patients carrying the Gly388 allele showed improved OS compared to those carrying Arg388. |
format | Online Article Text |
id | pubmed-4720088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-47200882016-01-27 The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy Shim, Hyun-Jeong Shin, Min-Ho Kim, Hee-Nam Kim, Jo-Heon Hwang, Jun-Eul Bae, Woo-Kyun Chung, Ik-Joo Cho, Sang-Hee Cancer Res Treat Original Article PURPOSE: The purpose of this study is to investigate the role of fibroblast growth factor receptor 4 (FGFR4) polymorphism in esophageal cancer after chemoradiotherapy (CRT). MATERIALS AND METHODS: Peripheral blood samples from 244 patients treated with CRT for esophageal squamous cell carcinoma were assessed for the role of FGFR4 genotype on treatment response and survival. RESULTS: A total of 94 patients were homozygous for the Gly388 allele, and 110 were heterozygous and 40 homozygous for the Arg388 allele. No significant association was found between the FGFR4 genotype and clinicopathological parameters. However, patients carrying the Gly388 allele showed a better overall response rate than Arg388 carriers (p=0.038). In addition, Gly388 allele patients at an earlier stage showed better overall survival (OS) and progression-free survival than Arg388 carriers. Among these, the Gly388 allele showed significantly improved OS compared to Arg388 carriers in the lymph node (LN) metastasis group (p=0.042) compared to the no LN metastasis group (p=0.125). However, similar survival outcomes were observed for advanced-stage disease regardless of genotype. CONCLUSION: This result suggests that the role of FGFR4 Gly388 in treatment outcomes differs according to esophageal cancer stage. It showed a predictive role in the response of esophageal cancer patients to CRT with a better trend for OS in Gly388 than Arg388 carriers in the early stages. In particular, LN-positive early-stage patients carrying the Gly388 allele showed improved OS compared to those carrying Arg388. Korean Cancer Association 2016-01 2015-05-14 /pmc/articles/PMC4720088/ /pubmed/25989802 http://dx.doi.org/10.4143/crt.2015.018 Text en Copyright © 2016 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Shim, Hyun-Jeong Shin, Min-Ho Kim, Hee-Nam Kim, Jo-Heon Hwang, Jun-Eul Bae, Woo-Kyun Chung, Ik-Joo Cho, Sang-Hee The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy |
title | The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy |
title_full | The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy |
title_fullStr | The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy |
title_full_unstemmed | The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy |
title_short | The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy |
title_sort | prognostic significance of fgfr4 gly388 polymorphism in esophageal squamous cell carcinoma after concurrent chemoradiotherapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720088/ https://www.ncbi.nlm.nih.gov/pubmed/25989802 http://dx.doi.org/10.4143/crt.2015.018 |
work_keys_str_mv | AT shimhyunjeong theprognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT shinminho theprognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT kimheenam theprognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT kimjoheon theprognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT hwangjuneul theprognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT baewookyun theprognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT chungikjoo theprognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT chosanghee theprognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT shimhyunjeong prognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT shinminho prognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT kimheenam prognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT kimjoheon prognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT hwangjuneul prognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT baewookyun prognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT chungikjoo prognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy AT chosanghee prognosticsignificanceoffgfr4gly388polymorphisminesophagealsquamouscellcarcinomaafterconcurrentchemoradiotherapy |